Luc Thaens SRL
Luc Thaens reported total assets of 204,672 € at the end of the 2025 financial year (annual accounts filed with the NBB on 29 Jun 2026).
The score of Luc Thaens shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +59 % Total assets +71 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Luc Thaens's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 39,409 € | ||||
| Equity | 176,447 € | ||||
| Cash | 71,906 € | ||||
| EBITDA | 59,478 € | ||||
| Total assets | 204,672 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 29 Jun 2026
- Year ended 31 Dec 2024filed on 30 May 2025
- Year ended 31 Dec 2023filed on 28 Jun 2024
- Year ended 31 Dec 2022filed on 30 Jun 2023
- Year ended 31 Dec 2021filed on 30 Jun 2022
Luc Thaens's financial analysis
- Solvency86.2%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Luc Thaens
Luc Thaens's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0871.255.087
- VAT number
- BE0871255087
- Peppol
- Registered · 0208:0871255087 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 17 Jan 2005
- Registered office
- 3550 Heusden-Zolder
- Latest accounts
- 2025 · filed on 29 Jun 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Luc Thaens (SRL) has been based in Heusden-Zolder since 2005, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 39,409 € and equity of 176,447 €; its revenue is not published. Its solvency stands at 86.2%, above the median of its sector (44.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Luc Thaens
Companies in the same business, of comparable size and area, outside its group.
- Walpharma Retail sale of pharmaceutical products Arlon · balance sheet 202,753 €
- Pharmacie Chaussee de Gand Retail sale of pharmaceutical products Molenbeek-Saint-Jean · balance sheet 199,651 €
- Apotheek van Dionant Retail sale of pharmaceutical products Beersel · balance sheet 229,148 €
- Melbuj Retail sale of pharmaceutical products Wemmel · balance sheet 237,909 €
- Somad Retail sale of pharmaceutical products Frameries · balance sheet 170,686 €
- PTMS Consultancy Retail sale of pharmaceutical products Londerzeel · balance sheet 192,606 €
- Vivapharma Retail sale of pharmaceutical products Auderghem · balance sheet 236,296 €
- I & CM Marbotin Retail sale of pharmaceutical products Schaerbeek · balance sheet 323,588 €
Frequently asked questions about Luc Thaens
What is the revenue of Luc Thaens?
Luc Thaens files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Luc Thaens?
In Belgium, the VAT number is the company number prefixed with BE: BE0871255087 for Luc Thaens, if the company is VAT-registered. Its company number (CBE) is 0871.255.087.
Where is the registered office of Luc Thaens?
According to the CBE register, the registered office of Luc Thaens is in 3550 Heusden-Zolder.
What is the equity of Luc Thaens?
At the close of the 2025 financial year, the equity of Luc Thaens amounts to 176,447 €, a solvency of 86.2% of total assets.
Who manages Luc Thaens?
The register lists 1 active mandates at Luc Thaens. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Luc Thaens
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →